Blockade of TIGIT-PVR Axis can Treat Breast Cancer

Authors

  • Ana Hernandez Garcia University of Kansas, School of Professional Studies, Biotechnology

DOI:

https://doi.org/10.17161/mjusc.v1i1.18570

Keywords:

TIGIT, Checkpoint Inhibitor, Cancer, Breast, PVR, immunology

Abstract

This review covers the identification and application of anti-TIGIT antibodies as checkpoint inhibitors for the treatment of triple-negative breast cancers. The original article, Targeting the TIGIT-PVR Immune Checkpoint Axis as Novel Therapeutic Option in Breast Cancer, was published by Stamm et al. in Oncoimmunology in October of 2019.

Cover of issue 1 of the Midwestern Journal of Undergraduate Sciences showing an illustration of checkpoint inhibitors

Downloads

Published

2022-10-03

Issue

Vol. 1 No. 1 (2022)

Section

Reviews

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© The Author(s)

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license. 

How to Cite

Hernandez Garcia, A. (2022). Blockade of TIGIT-PVR Axis can Treat Breast Cancer. Midwestern Journal of Undergraduate Sciences, 1(1), 5. https://doi.org/10.17161/mjusc.v1i1.18570